Login
Companies $LNTH
$101.72 +$0.13 (0.13%) Live
Lantheus Holdings, Inc. logo

Lantheus Holdings, Inc.

lantheus.com

What Do They Do?

Sells PYLARIFY, a PET imaging agent for prostate cancer, alongside diagnostic imaging products and microbubbles to hospitals, imaging centers and government facilities.

Who Are Their Customers?

U.S. customers are mainly hospitals, imaging centers and government facilities, alongside other medical buyers. Outside the U.S., Lantheus sells directly in some markets, through third-party distributors in others, and licenses rights to develop and commercialize certain products.

Do Revenues Turn Into Profits?

Yes. It kept 15 cents of every revenue dollar as net income in FY2025 and turned 23 cents into free cash flow.

Operating income, FY2025
20% of revenue
▼ −32% vs FY2024 ($457M, 30%)
Net income, FY2025
15% of revenue
▼ −25% vs FY2024 ($312.4M, 20%)
Free cash flow, FY2025
23% of revenue
▼ −28% vs FY2024 ($493.1M, 32%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +2%
vs $384M in Q3 FY2025
Net income
▼ −19%
vs $27.8M in Q3 FY2025
Product revenue, net share of revenue vs 98.1% in Q3 FY2025
  • Nov 5, 2026 Suspended full-year 2026 guidance amid the pending merger The company said it would suspend its previously issued guidance in connection with the proposed Curium transaction.
  • Oct 21, 2026 FTC requested more information on the proposed merger The request extends the antitrust waiting period; the parties still expect to close in the first half of 2027.
  • Aug 1, 2026 Agreed to merge with Curium The agreement provides for $102.50 per share in cash and a contingent value right for up to $12.00, subject to milestones.

Sale of SPECT business The earlier report listed SPECT products including TechneLite, NEUROLITE, Xenon and CARDIOLITE; the latest says the company sold its SPECT business and associated products to SHINE.

AZEDRA production ended The earlier report included AZEDRA as a commercial cancer treatment; the latest says production has been discontinued.

RELISTOR royalty rights sold The earlier report says Lantheus collected quarterly royalties for RELISTOR; the latest says it sold those royalty rights and retained rights to future sales-based milestone payments.

Revenue over time
Product revenue, net License and royalty revenues Total radiopharmaceutical oncology Total precision diagnostics Strategic partnerships and other revenue
$2B$1B$0

Who Do They Compete With?

Competes with Telix Pharmaceuticals, Blue Earth Diagnostics, Novartis, GE Healthcare, Bracco, Lilly, ITM Radiopharma, Curium, and RayzeBio

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support